DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances Notice of Registration

By Notice dated August 28, 2009, and published in the Federal Register on September 8, 2009, (74 FR 46231), Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dihydromorphine (9145)</td>
<td>I</td>
</tr>
<tr>
<td>Amphetamine (1100)</td>
<td>II</td>
</tr>
<tr>
<td>Methamphetamine (1105)</td>
<td>II</td>
</tr>
<tr>
<td>Amobarbital (2125)</td>
<td>II</td>
</tr>
<tr>
<td>Pentobarbital (2270)</td>
<td>II</td>
</tr>
<tr>
<td>Secobarbital (2315)</td>
<td>II</td>
</tr>
<tr>
<td>Phenylacetonide (8501)</td>
<td>II</td>
</tr>
<tr>
<td>Cocaine (9041)</td>
<td>II</td>
</tr>
<tr>
<td>Codeine (9050)</td>
<td>II</td>
</tr>
<tr>
<td>Dihydrocodein (9120)</td>
<td>II</td>
</tr>
<tr>
<td>Oxycodeine (9143)</td>
<td>II</td>
</tr>
<tr>
<td>Hydromorphone (9150)</td>
<td>II</td>
</tr>
<tr>
<td>Diphenoxylate (9170)</td>
<td>II</td>
</tr>
<tr>
<td>E-codeine (9180)</td>
<td>II</td>
</tr>
<tr>
<td>Hydrocodone (9193)</td>
<td>II</td>
</tr>
<tr>
<td>Meperidine (9230)</td>
<td>II</td>
</tr>
<tr>
<td>Methadone (9250)</td>
<td>II</td>
</tr>
<tr>
<td>Morphine (9300)</td>
<td>II</td>
</tr>
<tr>
<td>Oxymorphone (9652)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cody Laboratories to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cody Laboratories to ensure that the company’s registration is consistent with the public interest.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–515 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated August 28, 2009, and published in the Federal Register on September 8, 2009, (74 FR 46231), Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II.

The company plans on manufacturing a radioactive product used in diagnostic imaging in the diagnosis of Parkinson’s Disease and for manufacture in bulk for investigational new drug (IND) submission and clinical trials.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of GE Healthcare to manufacture the listed basic class of controlled substance is consistent with the public interest at this time.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–515 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P
the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–509 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated August 28, 2009, and published in the Federal Register on September 8, 2009, (74 FR 46232), Noramco Inc., Division of Ortho McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801–4417, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II.

The company plans to bulk manufacture the listed controlled substance as a reference standard for distribution to its customers which are analytical laboratories.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Noramco Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–509 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated August 28, 2009, and published in the Federal Register on September 8, 2009, (74 FR 46233), National Center for Natural Products Research-NIDA MProject, University of Mississippi, 135 Coy Waller Lab Complex, University, Mississippi 38677, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marihuana (7360)</td>
<td>I</td>
</tr>
<tr>
<td>Tetrahydrocannabinols (7370)</td>
<td>I</td>
</tr>
</tbody>
</table>

The company plans to cultivate marihuana for the National Institute on Drug Abuse for research approved by the Department of Health and Human Services.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of National Center for Natural Products Research-NIDA MProject to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated National Center for Natural Products Research-NIDA MProject to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–509 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

National Institute of Corrections

Solicitation for a Cooperative Agreement—Training for Correctional Industries Directors

AGENCY: National Institute of Corrections, Department of Justice.

ACTION: Solicitation for a cooperative agreement.

SUMMARY: The National Institute of Corrections’ (NIC) Transition and Offender Workforce Development (T/OWD) and Academy Divisions are seeking applications for the development of a competency based, blended modality training curriculum that will provide Correctional Industries Directors with the knowledge, skills and abilities needed to set organizational priorities, identify strategic objectives, create measurable goals, establish collaborative partnerships, utilize current labor market information, and provide specialized services and programming that support the offenders’ long term attachment to the labor force.

DATES: Applications must be received by 4 p.m. EST on Friday, February 12, 2010.

ADDRESSES: Mailed applications must be sent to: Director, National Institute of Corrections, 320 First Street, NW., Room 5007, Washington, DC 20534. Applicants are encouraged to use Federal Express, UPS, or similar service to ensure delivery by the due date.

Hand delivered applications should be brought to 500 First Street, NW., Washington, DC 20534. At the front desk, dial 7–3106, extension 0 for pickup.

Fax applications will not be accepted. Electronic applications can be submitted via http://www.grants.gov.

FOR FURTHER INFORMATION CONTACT: All technical or programmatic questions concerning this announcement should be directed to Michael Guevara, Correctional Program Specialist, National Institute of Corrections. He can be reached by calling 303–365–4415, or by e-mail at mguevara@bop.gov.

Questions will be accepted until one week prior to the application due date. At this time responses to the questions will be posted on the NIC Web site.

SUPPLEMENTARY INFORMATION: Overview: NIC is looking to develop a curriculum, which follows NIC’s Instructional Theory Into Practice (ITIP) model, to be written based on occupational documentation that includes a completed DACUM (Developing A Curriculum) and a